| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
In cultured vascular cells, l-mimosine acted as a prolyl 4-hydroxylase inhibitor. L-mimosine inhibited prolyl hydroxylase activity in rat and human smooth muscle cells (SMC) dose-dependently, and at concentrations of 400–500 M reduced hydroxyprolyl generation by 80–90%. At that concentration, [3H]proline incorporation decreased by about 20% in human SMC while increasing by about 20% in rat SMC. These findings showed that L-mimosine very specifically inhibited prolyl hydroxylation.
| ln Vitro |
L-Mimosine reduces cell proliferation by halting the cell cycle in PC-3 cells at the G1 phase and in LNCaP cells at the S phase. [1] L-mimosine, a prolyl hydroxylase (PHD) inhibitor, stimulates the synthesis of VEGF and boosts the proangiogenic potential of cells derived from dental pulp. [2]
|
||
|---|---|---|---|
| ln Vivo |
In Sprague-Dawley rats, L-mimosine (50 mg/kg i.p.) significantly increases the expression of HIF-1alpha in the kidneys and noticeably improves the natriuretic response to renal perfusion pressure. [3]
|
||
| Enzyme Assay |
In rats, it interfered with the reconstitution of the active human prolyl 4-hydroxylase with an IC50 value of 120 µM.
|
||
| Cell Assay |
Cell proliferation in response to L-mimosine is measured using a [3H]thymidine incorporation assay. In this test, RPMI-1640 medium with 10% FCS and various concentrations of L-mimosine (0-800 μM) are cultured in each well of a 12-well plate with 1 × 104 cells each. Each well of the 12-well plate receives 0.5 μCi/ml of [3H[3H]thymidine following the necessary incubation times (24 and 48 h). After that, the cells are incubated for 4 hours at 37°C in a humidified 5% CO2 environment. The following step involves washing the cells twice in cold phosphate-buffered saline (PBS) and once more in cold 5% trichloroacetic acid. By adding 0.5 ml of 0.5 N NaOH, cells are lysed. In a liquid scintillation analyzer, 400 μl of the solubilized cell solution are combined with 4 ml of scintillation cocktail, and the results are then tallied. Quadruplicates of each sample were examined.
|
||
| Animal Protocol |
|
||
| ADME/Pharmacokinetics |
Metabolism / Metabolites
EXPERIMENTAL POISONING OF SHEEP HAS SHOWN THAT MIMOSINE IS LARGELY BROKEN DOWN IN THE RUMEN TO 3,4-DIHYDROXYPYRIDINE, AND EXCRETED AS SUCH. /MIMOSINE/ |
||
| Toxicity/Toxicokinetics |
Protein Binding
>99.5% |
||
| References | |||
| Additional Infomation |
L-mimosine is an L-alpha-amino acid that is propionic acid substituted by an amino group at position 2 and a 3-hydroxy-4-oxopyridin-1(4H)-yl group at position 3 (the 2S-stereoisomer). It a non-protein plant amino acid isolated from Mimosa pudica. It has a role as an EC 1.14.18.1 (tyrosinase) inhibitor and a plant metabolite. It is a non-proteinogenic L-alpha-amino acid and a member of 4-pyridones. It is functionally related to a propionic acid. It is a conjugate acid of a L-mimosine(1-). It is a tautomer of a L-mimosine zwitterion.
Mimosine is an antineoplastic alanine-substituted pyridine derivative isolated from Leucena glauca. L-mimosine has been reported in Arabidopsis thaliana, Euglena gracilis, and Caenorhabditis elegans with data available. 3-Hydroxy-4-oxo-1(4H)-pyridinealanine. An antineoplastic alanine-substituted pyridine derivative isolated from Leucena glauca. Mechanism of Action Mimosine causes inhibition of DNA replication, changes in the progression of the cells in the cell cycle, and apoptosis. Mimosine appears to introduce breaks into DNA. Mimosine is an iron/zinc chelator. Iron depletion induces DNA double-strand breaks in treated cells, and activates a DNA damage response that results in focal phosphorylation of histones. This leads to inhibition of DNA replication and/or DNA elongation. Some studies indicate that mimosine prevents the initiation of DNA replication, whereas other studies indicate that mimosine disrupts elongation of the replication fork by impairing deoxyribonucleotide synthesis by inhibiting the activity of the iron-dependent enzyme ribonucleotide reductase and the transcription of the cytoplasmic serine hydroxymethyltransferase gene (SHMT). Inhibition of serine hydroxymethyltransferase is moderated by a zinc responsive unit located in front of the SHMT gene. Pharmacodynamics Mimosine inhibits DNA synthesis at the level of elongation of nascent chains by altering deoxyribonucleotide metabolism. It arrests the cell cycle in the late G(1) phase. |
| Molecular Formula |
C8H10N2O4
|
|
|---|---|---|
| Molecular Weight |
198.18
|
|
| Exact Mass |
198.064
|
|
| Elemental Analysis |
C, 48.49; H, 5.09; N, 14.14; O, 32.29
|
|
| CAS # |
500-44-7
|
|
| Related CAS # |
|
|
| PubChem CID |
440473
|
|
| Appearance |
CRYSTALS FROM WATER
TABLETS FROM WATER |
|
| Density |
1.544g/cm3
|
|
| Boiling Point |
428.6ºC at 760mmHg
|
|
| Melting Point |
224-228 °C
|
|
| Flash Point |
213ºC
|
|
| Index of Refraction |
1.645
|
|
| LogP |
-3.5
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
6
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
14
|
|
| Complexity |
321
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
N[C@@H](CN1C=C(C(C=C1)=O)O)C(O)=O
|
|
| InChi Key |
WZNJWVWKTVETCG-YFKPBYRVSA-N
|
|
| InChi Code |
InChI=1S/C8H10N2O4/c9-5(8(13)14)3-10-2-1-6(11)7(12)4-10/h1-2,4-5,12H,3,9H2,(H,13,14)/t5-/m0/s1
|
|
| Chemical Name |
(2S)-2-amino-3-(3-hydroxy-4-oxopyridin-1-yl)propanoic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.03.00
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2 mg/mL (10.09 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0459 mL | 25.2296 mL | 50.4592 mL | |
| 5 mM | 1.0092 mL | 5.0459 mL | 10.0918 mL | |
| 10 mM | 0.5046 mL | 2.5230 mL | 5.0459 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
